Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Advanced Biomed Inc. before investing.

In this article, we go over a few key elements for understanding Advanced Biomed Inc.’s stock price such as:

• Advanced Biomed Inc.’s current stock price and volume
• Why Advanced Biomed Inc.’s stock price changed recently
• Upgrades and downgrades for ADVB from analysts
• ADVB’s stock price momentum as measured by its relative strength

About Advanced Biomed Inc. (ADVB)

Before we jump into Advanced Biomed Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People’s Republic of China. The company was founded in 2014 and is headquartered in New York, New York.

Want to learn more about Advanced Biomed Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Advanced Biomed Inc..

Advanced Biomed Inc.’s Stock Price as of Market Close

As of April 08, 2025, 12:53 PM, CST, Advanced Biomed Inc.’s stock price was $2.135.

Advanced Biomed Inc. is down 26.38% from its previous closing price of $2.900.

During the last market session, Advanced Biomed Inc.’s stock traded between $2.090 and $2.890. Currently, there are approximately 20.00 million shares outstanding for Advanced Biomed Inc..

Advanced Biomed Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Advanced Biomed Inc. Stock Price History

Advanced Biomed Inc.’s (ADVB) price is currently down 45.54% so far this month.

During the month of April, Advanced Biomed Inc.’s stock price has reached a high of $4.000 and a low of $2.090.

Over the last year, Advanced Biomed Inc. has hit prices as high as $4.100 and as low as $2.720.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Advanced Biomed Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 07, 2025, there were analysts who downgraded Advanced Biomed Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Advanced Biomed Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Advanced Biomed Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Advanced Biomed Inc. (ADVB) by visiting AAII Stock Evaluator.

Relative Price Strength of Advanced Biomed Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 07, 2025, Advanced Biomed Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Advanced Biomed Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Advanced Biomed Inc. Stock Price: Bottom Line

As of April 8, 2025, Advanced Biomed Inc.’s stock price is $2.135, which is down 26.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Advanced Biomed Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.